Literature DB >> 7286042

Acetylator phenotyping: a comparison of the isoniazid and dapsone tests.

A Hanson, A Melander, E Wåhlin-Boll.   

Abstract

A comparison was made between the results of acetylator phenotyping by isoniazid (INH) half-life measurements based on 5 samples (0-6 h), and by determination of the ratio of monoacetylated (MAD) to unchanged dapsone (DDS) in a single sample obtained 3 h after dapsone intake. In each of 44 subjects examined, there was unequivocal agreement about classification of the subject as a rapid (INH t1/2 less than 2 h; MAD/DDS greater than 0.3) or slow (INH t1/2 greater than 2 h; MAD/DDS less than 0.3) acetylator. It appears that the single-sample (3 h) dapsone test is as reliable as the more laborious and time-consuming INH test for acetylator phenotyping.

Entities:  

Mesh：

Substances：

Year:  1981        PMID： 7286042     DOI： 10.1007/BF00544604

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN： 0031-6970            Impact factor:   2.953


  7 in total

1.  HUMAN ACETYLATION POLYMORPHISM.

Authors:  D A EVANS; T A WHITE
Journal:  J Lab Clin Med       Date:  1964-03

2.  The quantitative determination of isoniazid and para-aminosalicylic acid in body fluids.

Authors:  J R MAHER; J M WHITNEY; J S CHAMBERS; D J STANONIS
Journal:  Am Rev Tuberc       Date:  1957-11

3.  Increased incidence of isoniazid hepatitis in rapid acetylators: possible relation to hydranize metabolites.

Authors:  J R Mitchell; U P Thorgeirsson; M Black; J A Timbrell; W R Snodgrass; W Z Potter; H R Jollow; H R Keiser
Journal:  Clin Pharmacol Ther       Date:  1975-07       Impact factor: 6.875

Review 4.  Disease and acetylation polymorphism.

Authors:  P K Lunde; K Frislid; V Hansteen
Journal:  Clin Pharmacokinet       Date:  1977 May-Jun       Impact factor: 6.447

5.  The polymorphic acetylation of dapsone in man.

Authors:  R Gelber; J H Peters; G R Gordon; A J Glazko; L Levy
Journal:  Clin Pharmacol Ther       Date:  1971 Mar-Apr       Impact factor: 6.875

6.  Polymorphic acetylation procainamide in man.

Authors:  M M Reidenberg; D E Drayer; M Levy; H Warner
Journal:  Clin Pharmacol Ther       Date:  1975-06       Impact factor: 6.875

7.  Simultaneous analysis of dapsone and monoacetyldapsone employing high performance liquid chromatography: a rapid method for determination of acetylator phenotype.

Authors:  K Carr; J A Oates; A S Nies; R L Woosley
Journal:  Br J Clin Pharmacol       Date:  1978-11       Impact factor: 4.335
  7 in total
  19 in total

1.  Biological monitoring of isocyanates and related amines. IV. 2,4- and 2,6-toluenediamine in hydrolysed plasma and urine after test-chamber exposure of humans to 2,4- and 2,6-toluene diisocyanate.

Authors:  T Brorson; G Skarping; C Sangö
Journal:  Int Arch Occup Environ Health       Date:  1991       Impact factor: 3.015

2.  A simple method for determining acetylator phenotype using isoniazid.

Authors:  A Hutchings; P A Routledge
Journal:  Br J Clin Pharmacol       Date:  1986-09       Impact factor: 4.335

Review 3.  Clinical pharmacokinetics of dapsone.

Authors:  J Zuidema; E S Hilbers-Modderman; F W Merkus
Journal:  Clin Pharmacokinet       Date:  1986 Jul-Aug       Impact factor: 6.447

4.  N-acetylation phenotyping with dapsone in a mainland Chinese population.

Authors:  Y Horai; H H Zhou; L M Zhang; T Ishizaki
Journal:  Br J Clin Pharmacol       Date:  1988-01       Impact factor: 4.335

5.  Acetylation polymorphism and leprosy.

Authors:  L C Eze; A N Okpogba; A U Ogan
Journal:  Biochem Genet       Date:  1990-02       Impact factor: 1.890

6.  Peripheral motor neuropathy caused by excessive intake of dapsone (Avlosulfon).

Authors:  I Rosén; R Sörnäs
Journal:  Arch Psychiatr Nervenkr (1970)       Date:  1982

7.  Acetylation and oxidation phenotypes in malignant lymphoma.

Authors:  P A Philip; H J Rogers; P G Harper
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

8.  A rapid method for determination of acetylation phenotype using dapsone.

Authors:  P A Philip; M S Roberts; H J Rogers
Journal:  Br J Clin Pharmacol       Date:  1984-04       Impact factor: 4.335

9.  Biological monitoring of isocyanates and related amines. III. Test chamber exposure of humans to toluene diisocyanate.

Authors:  G Skarping; T Brorson; C Sangö
Journal:  Int Arch Occup Environ Health       Date:  1991       Impact factor: 3.015

10.  Biological monitoring of isocyanates and related amines. I. Determination of 1,6-hexamethylene diamine (HDA) in hydrolysed human urine after oral administration of HDA.

Authors:  T Brorson; G Skarping; J F Sandström; M Stenberg
Journal:  Int Arch Occup Environ Health       Date:  1990       Impact factor: 3.015
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.